Condition: MCI · MCI-AD, Early Stage Alzheimer's Disease · Alzheimer's Disease · Sponsor: Medical University of Lodz
The goal of this clinical trial is to assess the degree of improvement in cognitive functions, including memory, attention, thinking, executive and language functions in diagnosed patients MCI and AD taking dimethyl fumarate 480 mg daily compared to patients taking placebo. Participant will be 55 to 90 years old, both genders. The main question it aims to answer is: Changing the degree of cognitive improvement based on the RBANS score among patients diagnosed with MCI and AD after completing dimethyl fumarate therapy test group compared to the placebo group.
This description comes directly from the study's public registry record.
Medical University of Lodz Medical University of Lodz · +48 422725239 · cwbk@umed.lodz.pl
Jakub Kazmierski, PhD · +48 426757372 · jakub.kazmierski@umed.lodz.pl
Always discuss trial participation with your own doctor first.
| Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz | Lodz, Łódź Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06850597